 Analysts at Citi have lowered their price target for GSK PLC LSE:GSK, NYSE:GSK to 1,545p from 1,975p to reflect the limited visibility investors enjoy over the ultimate magnitude of Zantac ulcer drug liabilities. This is coupled with negative prior expectations for the bellwether Zantac case in Oakland, California, scheduled for February 2023, they added. 